Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 90 of 6351
-
AI eye scanner could prevent blindness in millions with diabetes
Diagnosis Recruiting nowIn this pivotal trial, we aim to perform a prospective study to find the efficacy of iPredict-DR, an artificial intelligence (AI) based software tool on early diagnosis of Diabetic Retinopathy (DR) in the primary care and endocrinology clinics. DR is one of the leading causes of …
Sponsor: iHealthScreen Inc • Aim: Diagnosis
Last updated Jun 26, 2026 12:53 UTC
-
Can a new immune therapy help frail lung cancer patients live longer?
Disease control Recruiting nowThe SPACE-T study is a clinical trial for people with advanced small-cell lung cancer (SCLC) whose cancer has returned or spread despite previous treatment and whose general health is reduced (ECOG performance status 2). The study will include 57 participants at about 15 sites in…
Phase 2 • Sponsor: AIO-Studien-gGmbH • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a triple immunotherapy attack beat advanced melanoma?
Disease control Recruiting nowTo determine the recommended Phase IIa dose (RP2D) of the triplet combination. To determine the safety and efficacy of the combination at the RP2D.
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can poop pills beat superbugs? new trial aims to stop antibiotic resistance
Disease control Recruiting nowThe aim of this research experiment is to evaluate the effectiveness of fecal microbiota transplantation (FMT) preceded by antibiotic pre-treatment versus probiotic therapy and a standard-of-care equivalent diet designed to stimulate the growth of eubiotic gut microbiota (an acti…
Sponsor: Medical University of Warsaw • Aim: Disease control
Last updated Jun 26, 2026 12:32 UTC
-
Can a targeted drug outperform chemotherapy in Tough-to-Treat nasopharyngeal cancer?
Disease control OngoingThis study was designed to compare the efficacy and safety of YL201 with Investigator's choice of chemotherapy in subjects with recurrent or metastatic nasopharyngeal carcinoma who have failed prior PD-(L)1 inhibitor and at least two lines of chemotherapy.
Phase 3 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a Four-Drug cocktail tame a deadly lung complication of myositis?
Disease control Recruiting nowIdiopathic inflammatory myopathies (IIM) are a group of autoimmune conditions characterized by inflammation of muscles with possible extra-muscular manifestations which can include skin and interstitial lung disease (ILD). IIM-associated ILD carries poor prognosis. Particular sub…
Sponsor: Singapore General Hospital • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Electric pulses could zap lung tumors without surgery
Disease control Recruiting nowThe goal of this clinical trial is to verify the efficacy and safety of pulsed electric field (PEF) treatment of early-stage unreseectable non-small cell lung cancer(NSCLC) patients. The main questions it aims to answer are: * Safety of PEF treatment of early-stage unreseectabl…
Sponsor: Energenx Medical LTD. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
DNA blood test may spot nasopharyngeal cancer earlier than current methods
Diagnosis OngoingThis study focus on nasopharyngeal carcinoma, a cancer type with Chinese characteristics, analyze the early screening detection performance of nasopharyngeal carcinoma in the multi-cancer early screening model, and compare the performance differences among multi-omics models such…
Sponsor: First Affiliated Hospital, Sun Yat-Sen University • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
Light-Activated drug combo takes on recurrent head and neck cancer in major trial
Disease control Recruiting nowThe goal of this clinical trial is to learn if ASP-1929 photoimmunotherapy (PIT) in combination with pembrolizumab works to treat recurrent squamous cell cancer of the head and neck (HNSCC) with no distant metastases. It will also learn about the safety of ASP-1929 PIT in combina…
Phase 3 • Sponsor: Rakuten Medical, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Can a Two-Drug combo shrink Hard-to-Treat stomach tumors?
Disease control OngoingThis study is a multicenter, open-label, phase II clinical study to explore the safety and efficacy of BL-M07D1+PD-1 monoclonal antibody in patients with unresectable locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Phase 2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Immune cells from your own tumor could fight advanced melanoma
Disease control Recruiting now98 participants will be randomly assigned 1:1 to the experimental group and the control group for the Phase II clinical trial,this trail is expected to be finished in 24 months
Phase 2 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a Five-Part vaccine bolster protection against three serious infections?
Vaccine CompletedThis is a randomized, blinded, controlled phase II and III clinical trial evaluating the immunogenicity and safety of adsorbed cell-free DPT vaccine. 320 subjects aged 7 years and older in the phase II were divided into two age groups, the ≥18 years group and the 7-17 years group…
Phase 2/3 • Sponsor: CanSino Biologics Inc. • Aim: Vaccine
Last updated Aug 28, 2026 00:00 UTC
-
Engineered immune cells take on rare Muscle-Weakening disease
Disease control Recruiting nowRESET-MG: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Participants with Generalized Myasthenia Gravis
Phase 1/2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for myeloma patients: drug combo trial launches
Disease control Recruiting nowThe purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New two-drug combo aims to wipe out HER2 breast cancer before surgery
Disease control OngoingThis randomized, controlled, open-label, multicenter study will evaluate the safety and efficacy of KN026 in combination with HB1801 ± Carboplatin as neoadjuvant therapy in patients with early or locally advanced HER2-positive breast cancer.
Phase 3 • Sponsor: Shanghai JMT-Bio Inc. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Can engineered immune cells tame lupus? new trial hopes so.
Disease control Recruiting nowThis is a phase 1, open-label, non-randomized study enrolling pediatric and young adult research participants with treatment-refractory Systemic Lupus Erythematosus (SLE), to examine the safety, feasibility, and efficacy of administering T cell products derived from peripheral bl…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Immune cell boost: new hope for kids with tough neuroblastoma?
Disease control Recruiting nowThis is a phase II study looking at patient response to treatment with the combination dinutuximab, temozolomide, irinotecan, and GM-CSF.
Phase 2 • Sponsor: New Approaches to Neuroblastoma Therapy Consortium • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Can a new vaccine shield teens from meningitis?
Prevention CompletedThis is a randomized, blinded, peer-controlled study. There will be 2 treatment groups, screened subjects were given study numbers in the order of enrollment and randomly assigned to the test and control groups in a 1:1 ratio. Subjects were required to complete a 1-dose immunizat…
Phase 3 • Sponsor: CanSino Biologics Inc. • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
New heart pump trial aims to extend life for advanced heart failure patients
Disease control Recruiting nowThe purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.
Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Gene therapy injection aims to halt blindness from rare eye disorder
Disease control OngoingThis is a phase 3 study to evaluate the efficacy and safety of VGR-R01 in subjects with Bietti Crystalline Dystrophy. This is a multicenter, randomized controlled study which will enroll 45 subjects.
Phase 3 • Sponsor: Shanghai Vitalgen BioPharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC